Inclusion Criteria:  Patients aged 18-70 years; Diagnosed with PBC-AIH overlap syndrome according to Paris criteria; Agreed to participate in the trial, and assigned informed consent; The WBC count ≥2.5x10^9/L and platelet count ≥50x10^9/L.  Exclusion Criteria:  The presence of hepatitis A, B, C, D, or E virus infection; Patients with presence of serious decompensated cirrhosis; Patients have a history of glucocorticoid or immunosuppressant medication before enrollment; Liver damage caused by other reasons: such as primary sclerosing cholangitis, non-alcoholic steatohepatitis, drug induced liver disease or Wilson disease. Pregnant and breeding women; Severe disorders of other vital organs, such as severe heart failure, cancer; Parenteral administration of blood or blood products within 6 months before screening; Recent treatment with drugs having known liver toxicity; Taken part in other clinic trials within 6 months before enrollment.